Loading...
Cordlife Group Limited
CLIFF•PNK
Healthcare
Medical - Diagnostics & Research
$0.17
$0.00(0.00%)

Over the past four quarters, Cordlife Group Limited demonstrated steady revenue growth, increasing from $10.03M in Q3 2023 to $4.59M in Q2 2024. Operating income reached -$7.07M in Q2 2024, maintaining a consistent -154% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$6.84M, reflecting operational efficiency. Net income rose to -$6.18M, with EPS at -$0.02. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan